Mesoblast (MESO) said Sunday it has entered into the Medicaid National Drug Rebate Agreement with the US Centers for Medicare and Medicaid Services for Ryoncil, a US Food and Drug Administration therapy for any indication.

The agreement means that the US government will provide inpatient and outpatient access to Ryoncil as a treatment for children with steroid-refractory acute graft versus host disease who are covered by Medicaid.

The company said the first three children with the life-threatening condition that often follows organ transplants will receive a course of Ryoncil beginning this week.